PWPS
SMMT icon

Pinnacle Wealth Planning Services’s Summit Therapeutics SMMT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.8K Buy
3,140
+2,996
+2,081% +$53.1K ﹤0.01% 1333
2026
Q1 		$2.73K Buy
+144
New +$2.33K ﹤0.01% 2390

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pinnacle Wealth Planning Services's SMMT Position: Q2 2026 in Review

Pinnacle Wealth Planning Services increased its Summit Therapeutics (SMMT) stake by 2,081% in Q2 2026, buying an estimated $53.1K and bringing the position to 3,140 shares worth $45.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1333.

Pinnacle Wealth Planning Services first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Pinnacle Wealth Planning Services held 3,140 shares of Summit Therapeutics worth $45.8K as of Q2 2026.
  • Pinnacle Wealth Planning Services bought 2,996 Summit Therapeutics shares in Q2 2026, an estimated $53.1K.
  • Summit Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #1333 holding.
  • Pinnacle Wealth Planning Services first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.